Advanced glycation end-products (AGEs) constitute a non-homogenous, chemically diverse
group of compounds formed either exogeneously or endogeneously on the course of …

The stealth effect plays a central role on capacitating nanomaterials for drug delivery
applications through improving the pharmacokinetics such as blood circulation …

Cancer nanomedicines were initially envisioned as magic bullets, travelling through the
circulation to target tumours while sparing healthy tissues the toxicity of classic …

Over the past decades, lipid‐based nanoparticle drug delivery systems (DDS) have caught
the attention of researchers worldwide, encouraging the field to rapidly develop improved …

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease that encompasses a
spectrum of pathological conditions, ranging from simple steatosis (NAFL), nonalcoholic …

Lipid nanoparticles (LNPs) are the leading nonviral technologies for the delivery of
exogenous RNA to target cells in vivo. As systemic delivery platforms, these technologies …

Inflammation-associated diseases encompass a range of infectious diseases and non-
infectious inflammatory diseases, which continuously pose one of the most serious threats to …

Hereditary genetic disorders, cancer, and infectious diseases of the liver affect millions of
people around the globe and are a major public health burden. Most contemporary …

Gene therapy is a promising strategy for the treatment of monogenic disorders. Non-viral
gene delivery systems including lipid-based DNA therapeutics offer the opportunity to …

Extracellular vesicles (EVs) are released by most cell types but providing evidence for their
physiological relevance remains challenging due to a lack of appropriate model organisms …